House passes pediatric bill
Executive Summary
House passes legislation codifying FDA's "pediatric rule" Nov. 19 by unanimous consent. Senate passed same language (S 160/HR 2957) in July following federal court ruling that FDA lacked statutory authority to require drug studies in children (1"The Pink Sheet" July 28, 2003, p. 4). President Bush is expected to sign the bill into law...
You may also be interested in...
FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.